Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DYAX: Dyax Corp. -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (9)	5/22/2001 7:18:03 AM
From: nigel bates	Respond to of 197

-- Dyax Discovers Affinity Ligand to Chemically Purify AHP's Factor VIII for The Treatment of Type A Hemophilia -- CAMBRIDGE, Mass., May 22 /PRNewswire/ --Dyax Corp. (Nasdaq: DYAX - news) today announced it has entered into a license agreement with Wyeth-Genetics Institute-the biotechnology unit of American Home Products Corporation (NYSE: AHP - news). The commercial license is for a unique, chemically synthesizable ligand, discovered by Dyax, that has high capacity as well as specificity for purification of Wyeth-Genetics Institute's proprietary Factor VIII molecule, ReFacto. ``This ligand is a breakthrough for the purification of Factor VIII because it is chemically synthesizable, allowing us to eliminate the use of animal- sourced ligands in our manufacturing process,'' said Dr. S. Robert Adamson, Vice President of Process and Product Development at Wyeth-Genetics Institute. ``We are very impressed with Dyax's phage display technology as a means of improving the purification of biopharmaceutical products, such as ReFacto.'' Under the terms of the license agreement, Wyeth-Genetics Institute has received an exclusive license for the use of Dyax's peptide ligands discovered specifically for the purification of recombinant Factor VIII. The commercial terms of the agreement were not disclosed. ``This agreement further demonstrates the power of phage display in the field of protein manufacturing, where purification efficiencies can make a tremendous difference in the purity and final cost of manufacture,'' said Henry Blair, Chairman and Chief Executive Officer of Dyax Corp....